Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.
An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.
Hear from our CEO, Dr. Adam Mendelsohn, on our revolutionary approach to challenges associated with patient behavior.NPM-115 is a miniature, six-month, subdermal, high-dose exenatide drug implant under development for chronic weight management in patients who are obese or overweight. This implant can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months. Our First-in-Human study, also known as LIBERATE-1 and supportive of NPM-115, is designed to study our exenatide implant in obese and overweight individuals.
NPM-119 is a miniature, six-month, subdermal, exenatide drug implant under development to treat patients with type 2 diabetes. This device can also be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.